Treatment options in recurrent cervical cancer (Review)

Gadducci,Angiolo; Tana,Roberta; Cosio,Stefania; Cionini,Luca

doi:10.3892/ol_00000001

Treatment options in recurrent cervical cancer (Review)

Authors:
- Angiolo Gadducci
- Roberta Tana
- Stefania Cosio
- Luca Cionini
View Affiliations

Affiliations: Department of Procreative Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa 56127, Italy. a.gadducci@obgyn.med.unipi.it
Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000001
Pages: 3-11

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The management of recurrent cervical cancer depends mainly on previous treatment and on the site and extent of recurrence. Concurrent cisplatin-based chemo-radiation is the treatment of choice for patients with pelvic failure after radical hysterectomy alone. However, the safe delivery of high doses of radiotherapy is much more difficult in this clinical setting compared with primary radiotherapy. Pelvic exenteration usually represents the only therapeutic approach with curative intent for women with central pelvic relapse who have previously received irradiation. In a recent series, the 5-year overall survival and operative mortality after pelvic exenteration ranged from 21 to 61% and from 1 to 10%, respectively. Free surgical margins, negative lymph nodes, small tumour size and long disease-free interval were associated with a more favourable prognosis. Currently, pelvic reconstructive procedures (continent urinary conduit, low colorectal anastomosis, vaginal reconstruction with myocutaneous flaps) are strongly recommended after exenteration. Concurrent cisplatin-based chemo-radiation is the treatment of choice for isolated para-aortic lymph node failure, with satisfactory chances of a cure in asymptomatic patients. Chemotherapy is administered with palliative intent to women with distant or loco-regional recurrences not amenable by surgery or radiotherapy. Cisplatin is the most widely used drug, with a response rate of 17-38% and a median overall survival of 6.1-7.1 months. Cisplatin-based combination chemotherapy achieves higher response rates (22-68%) when compared with single-agent cisplatin, but median overall survival is usually less than one year. In a recent Gynecologic Oncology Group (GOG) trial the combination topotecan + cisplatin obtained a significantly longer overall survival than single-agent cisplatin in patients with metastatic or recurrent or persistent cervical cancer. A subsequent GOG study showed a trend in terms of longer overall survival and better quality of life for the doublet cisplatin + paclitaxel vs. the doublets cisplatin + topotecan, cisplatin + vinorelbine, and cisplatin + gemcitabine. Molecularly targeted therapy may represent a novel therapeutic tool, but its use alone or in combination with chemotherapy is still investigational.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Bellone S, Pecorelli S, Cannon MJ and Santin AD: Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther. 7:1473–1486. 2007. View Article : Google Scholar : PubMed/NCBI
3	Leitao MM and Chi DS: Recurrent cervical cancer. Curr Treat Options Oncol. 3:105–111. 2002. View Article : Google Scholar
4	Friedlander M: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist. 7:342–347. 2002.PubMed/NCBI
5	Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz APM, Ngan HYS and Pecorelli S: Carcinoma of the cervix uteri. Int J Gynecol Obstet. 95(Suppl 1): 43–103. 2006. View Article : Google Scholar
6	Dornhöfer N and Höckel M: New developments in the surgical therapy of cervical carcinoma. Ann NY Acad Sci. 1138:233–252. 2008.
7	Höckel M: Pelvic recurrences of cervical cancer. Relapse pattern, prognostic factors and the role of extended radical treatment. J Pelv Surg. 5:255–266. 1999.
8	Zatoński W and Tyczyński J: Cancer in Poland in 1993. Zakład Epidemiologii i Prewencji Nowotworów. Krajowy Rejestr Nowotworów; Warszawa: pp. 22–41. 1996
9	Panek G, Gawrychowski K, Sobiczewski P, Derlatka P, Danska-Bidzinska A, Gmyrek L and Bidzinski M: Results of chemotherapy for pulmonary metastases of carcinoma of the cervix in patients after primary surgical and radiotherapeutic management. Int J Gynecol Cancer. 17:1056–1061. 2007. View Article : Google Scholar : PubMed/NCBI
10	Zola P, Fuso L, Mazzola S, Piovano E, Perotto S, Gadducci A, Galletto L, Landoni F, Maggino T, Raspagliesi F, Sartori E and Scambia G: Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis. Gynecol Oncol. 107(Suppl 1): 150–154. 2007. View Article : Google Scholar
11	Potter ME, Alvarez RD, Gay FL, Shingleton HM, Soong SJ and Hatch KD: Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol. 37:74–77. 1990. View Article : Google Scholar : PubMed/NCBI
12	Malfetano J, Keys H, Kredentser D, Cunningham M, Kotlove D and Weiss L: Weekly cisplatin and radical radiation therapy for advanced, recurrent and poor prognosis cervical carcinoma. Cancer. 71:3703–3706. 1993. View Article : Google Scholar : PubMed/NCBI
13	Ijaz T, Eifel PJ, Burke T and Oswald MJ: Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. Gynecol Oncol. 70:241–246. 1998. View Article : Google Scholar : PubMed/NCBI
14	Smaniotto D, D’Agostino G, Luzi S, Valentini V, Macchia G, Mantini G, Margariti PA, Ferrandina G and Scambia G: Concurrent 5-fluorouracil, mitomycin C and radiation with or without brachytherapy in recurrent cervical cancer: a scoring system to predict clinical response and outcome. Tumori. 91:295–301. 2005.
15	Windschall A, Ott OJ, Sauer R and Strnad V: Radiation therapy and simultaneous chemotherapy for recurrent cervical carcinoma. Strahlenther Onkol. 181:545–550. 2005. View Article : Google Scholar : PubMed/NCBI
16	Miglietta L, Franzone P, Centurioni MG, Boni L, Tacchini L, Cosso M, Boccardo F, Ferrarini M and Bruzzone M: A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer. Oncology. 70:19–24. 2006. View Article : Google Scholar
17	Jain P, Hunter RD, Livsey JE, Coyle C, Swindell R and Davidson SE: Salvaging locoregional recurrence with radiotherapy after surgery in early cervical cancer. Clin Oncol (R Coll Radiol). 19:763–768. 2007. View Article : Google Scholar : PubMed/NCBI
18	Piura B, Rabinovich A and Friger M: Recurrent cervical carcinoma after radical hysterectomy and pelvic lymph node dissection: a study of 32 cases. Eur J Gynaecol Oncol. 29:31–36. 2008.PubMed/NCBI
19	Barter JF, Soong SJ, Shingleton HM, Hatch KD and Orr JW Jr: Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol. 32:292–296. 1989. View Article : Google Scholar
20	Magrina JF: Complications of irradiation and radical surgery for gynecologic malignancies. Obstet Gynecol Surv. 48:571–575. 1993. View Article : Google Scholar : PubMed/NCBI
21	Mundt AJ, Roeske JC, Lujan AE, Yamada SD, Waggoner SE, Fleming G and Rotmensch J: Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 82:456–463. 2003. View Article : Google Scholar : PubMed/NCBI
22	Friedell GH, Cesare F and Parson L: Surgical treatment of cancer of the cervix recurring after primary irradiation therapy. N Engl J Med. 264:781–784. 1961. View Article : Google Scholar : PubMed/NCBI
23	Rubin SC, Hoskins WJ and Lewis JL: Radical hysterectomy for recurrent cervical cancer following radiation therapy. Gynecol Oncol. 27:316–324. 1987. View Article : Google Scholar : PubMed/NCBI
24	Terada K and Morley GW: Radical hysterectomy as surgical salvage therapy for gynecologic malignancy. Obstet Gynecol. 70:913–915. 1987.PubMed/NCBI
25	Rutledge S, Carey MS, Prichard H, Allen HH, Kocha W and Kirk ME: Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol Oncol. 52:353–359. 1994. View Article : Google Scholar : PubMed/NCBI
26	Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ and Rutledge FN: Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol. 55:29–35. 1994. View Article : Google Scholar : PubMed/NCBI
27	Maneo A, Landoni F, Cormio G, Colombo A and Mangioni C: Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. Int J Gynecol Cancer. 9:295–301. 1999. View Article : Google Scholar : PubMed/NCBI
28	Magrina JF: Types of pelvic exenterations: a reappraisal. Gynecol Oncol. 37:363–366. 1990. View Article : Google Scholar : PubMed/NCBI
29	Magrina JF, Stanhope CR and Weaver AL: Pelvic exenterations: supralevator, infralevator, and with vulvectomy. Gynecol Oncol. 64:130–135. 1997. View Article : Google Scholar : PubMed/NCBI
30	Chiva LM, Lapuente F, González-Cortijo L, González-Martín A, Rojo A, García JF and Carballo N: Surgical treatment of recurrent cervical cancer: state of the art and new achievements. Gynecol Oncol. 110(Suppl 2): 60–66. 2008. View Article : Google Scholar : PubMed/NCBI
31	Brunschwig A and Barber HR: Extended pelvic exenteration for advanced cancer of the cervix. Long survivals following added resection of involved small bowel. Cancer. 17:1267–1270. 1964. View Article : Google Scholar : PubMed/NCBI
32	Kiselow M, Butcher HR Jr and Bricker EM: Results of the radical surgical treatment of advanced pelvic cancer: a fifteen-year study. Ann Surg. 166:428–436. 1967.PubMed/NCBI
33	Creasman WT and Rutledge F: Is positive pelvic lymphadenopathy a contraindication to radical surgery in recurrent cervical carcinoma? Gynecol Oncol. 2:482–485. 1974. View Article : Google Scholar : PubMed/NCBI
34	Rutledge FN, Smith JP, Wharton JT and O’Quinn AG: Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol. 129:881–892. 1977.PubMed/NCBI
35	Symmonds RE, Pratt JH and Webb MJ: Exenterative operations: experience with 198 patients. Am J Obstet Gynecol. 121:907–918. 1975.PubMed/NCBI
36	Karlen JR and Piver MS: Reduction of mortality and morbidity associated with pelvic exenteration. Gynecol Oncol. 3:164–167. 1975. View Article : Google Scholar : PubMed/NCBI
37	Morley GW, Hopkins MP, Lindenauer SM and Roberts JA: Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol. 74:934–943. 1989.PubMed/NCBI
38	Shingleton HM, Soong SJ, Gelder MS, Hatch KD, Baker VV and Austin JM Jr: Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol. 73:1027–1034. 1989.PubMed/NCBI
39	Marnitz S, Köhler C, Müller M, Behrens K, Hasenbein K and Schneider A: Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol. 103:1023–1030. 2006. View Article : Google Scholar : PubMed/NCBI
40	Goldberg GL, Sukumvanich P, Einstein MH, Smith HO, Anderson PS and Fields AL: Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol. 101:261–268. 2006. View Article : Google Scholar : PubMed/NCBI
41	Berek JS, Howe C, Lagasse LD and Hacker NF: Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol. 99:153–159. 2005.PubMed/NCBI
42	Crozier M, Morris M, Levenback C, Lucas KR, Atkinson EN and Wharton JT: Pelvic exenteration for adenocarcinoma of the uterine cervix. Gynecol Oncol. 58:74–78. 1995. View Article : Google Scholar : PubMed/NCBI
43	Fleisch MC, Pantke P, Beckmann MW, Schnuerch HG, Ackermann R, Grimm MO, Bender HG and Dall P: Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol. 95:476–484. 2007. View Article : Google Scholar : PubMed/NCBI
44	Kinkel K, Ariche M, Tardivon AA, Spatz A, Castaigne D, Lhomme C and Vanel D: Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging. Radiology. 204:55–63. 1997. View Article : Google Scholar
45	Popovich MJ, Hricak H, Sugimura K and Stern JL: The role of MR imaging in determining surgical eligibility for pelvic exenteration. AJR Am J Roentgenol. 160:525–531. 1993. View Article : Google Scholar : PubMed/NCBI
46	Jeong YY, Kang HK, Chung TW, Seo JJ and Park JG: Uterine cervical carcinoma after therapy: CT and MR imaging findings. Radiographics. 23:969–981. 2003. View Article : Google Scholar : PubMed/NCBI
47	Elst P, Ahankour F and Tjalma W: Management of recurrent cervical cancer. Review of the literature and case report. Eur J Gynaecol Oncol. 28:435–441. 2007.PubMed/NCBI
48	Husain A, Akhurst T, Larson S, Alektiar K, Barakat RR and Chi DS: A prospective study of the accuracy of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol. 106:177–180. 2007. View Article : Google Scholar : PubMed/NCBI
49	Babar S, Rockall A, Goode A, Shepherd J and Reznek R: Magnetic resonance imaging appearances of recurrent cervical carcinoma. Int J Gynecol Cancer. 17:637–645. 2007. View Article : Google Scholar : PubMed/NCBI
50	Jover R, Lourido D, Gonzalez C, Rojo A, Gorospe L and Alfonso JM: Role of PET/CT in the evaluation of cervical cancer. Gynecol Oncol. 110(Suppl 2): 55–59. 2008. View Article : Google Scholar : PubMed/NCBI
51	Höckel M and Dornhöfer N: Pelvic exenteration for gynaecologic tumours: achievements and unanswered questions. Lancet Oncol. 7:837–847. 2006.
52	Plante M and Roy M: Operative laparoscopy prior to a pelvic exenteration in patients with recurrent cervical cancer. Gynecol Oncol. 69:94–99. 1998. View Article : Google Scholar : PubMed/NCBI
53	Kohler C, Tozzi R, Possover M and Schneider A: Explorative laparoscopy prior to exenterative surgery. Gynecol Oncol. 86:311–315. 2002. View Article : Google Scholar : PubMed/NCBI
54	Stein P, Daneshmand S, Dunn M, Garcia M, Lieskovsky G and Skinner DG: Continent right colon reservoir using a cutaneous appendicostomy. Urology. 63:577–580. 2004. View Article : Google Scholar : PubMed/NCBI
55	Rowland RG and Kropp BP: Evolution of the Indiana continent urinary reservoir. J Urol. 152:2247–2251. 1994.PubMed/NCBI
56	Bihrle R: The Indiana pouch continent urinary reservoir. Urol Clin North Am. 24:773–779. 1997. View Article : Google Scholar : PubMed/NCBI
57	Salom EM, Mendez LE, Schey D, Lambrou N, Kassira N, Gómez-Marn O, Averette H and Peñalver M: Continent ileocolonic urinary reservoir (Miami pouch): the University of Miami experience over 15 years. Am J Obstet Gynecol. 190:994–1003. 2004.PubMed/NCBI
58	Angioli R, Benedetti Panici P, Mirhashemi R, Mendez L, Cantuaria G, Basile S and Penalver M: Continent urinary diversion and low colorectal anastomosis after pelvic exenteration. Quality of life and complication risk. Crit Rev Oncol Hematol. 48:281–285. 2003. View Article : Google Scholar : PubMed/NCBI
59	Benedetti Panici P, Angioli R, Plotti F, Muzii L, Zullo MA, Manci N, Palaia I and Galluci M: Continent ileocolonic urinary diversion (Rome pouch) for gynecologic malignancies: technique and feasibility. Gynecol Oncol. 107:194–199. 2007.PubMed/NCBI
60	Hatch KD, Gelder MS, Soong SJ, Baker VV and Shingleton HM: Pelvic exenteration with low rectal anastomosis: survival, complications, and prognostic factors. Gynecol Oncol. 38:462–467. 1990. View Article : Google Scholar : PubMed/NCBI
61	Rietjens M, Maggioni A, Bocciolone L, Sideri M, Youssef O and Petit JY: Vaginal reconstruction after extended radical pelvic surgery for cancer: comparison of two techniques. Plast Reconstr Surg. 109:1592–1599. 2002. View Article : Google Scholar : PubMed/NCBI
62	Green AE, Escobar PF, Neubaurer N, Michener CM and Vongruenigen VE: The Martius flap neovagina revisited. Int J Gynecol Cancer. 15:964–966. 2005. View Article : Google Scholar : PubMed/NCBI
63	O’Connell C, Mirhashemi R, Kassira N, Lambrou N and McDonald WS: Formation of functional neovagina with vertical rectus abdominis musculocutaneous (VRAM) flap after total pelvic exenteration. Ann Plast Surg. 55:470–473. 2005.PubMed/NCBI
64	Del Carmen MG, McIntyre JF and Goodman A: The role of intraoperative radiation therapy (IORT) in the treatment of locally advanced gynecologic malignancies. Oncologist. 5:18–25. 2000.PubMed/NCBI
65	Gemignani ML, Alektiar KM, Leitao M, Mychalczak B, Chi D, Venkatraman E, Barakat RR and Curtin JP: Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int J Radiat Oncol Biol Phys. 50:687–694. 2001. View Article : Google Scholar : PubMed/NCBI
66	Hicks ML, Piver MS, Mas E, Hempling RE, Mcauley M and Walsh DL: Intraoperative orthovoltage radiation therapy in the treatment of recurrent gynecologic malignancies. Am J Clin Oncol. 16:497–500. 1993. View Article : Google Scholar : PubMed/NCBI
67	Höckel M: Laterally extended endopelvic resection: novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall. Gynecol Oncol. 91:369–377. 2003.
68	Höckel M: Laterally extended endopelvic resection (LEER) – principles and practice. Gynecol Oncol. 111:S13–S17. 2008.
69	Lopez-Graniel C, Dolores R, Cetina L, Gonzalez A, Cantu D, Chanona J, Uribe J, Candelaria M, Brom R, de la Garza J and Duenas-Gonzalez A: Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer. BMC Cancer. 5:1182005. View Article : Google Scholar : PubMed/NCBI
70	Hogg R and Friedlander M: Role of systemic chemotherapy in metastatic cervical cancer. Expert Rev Anticancer Ther. 3:234–240. 2003. View Article : Google Scholar : PubMed/NCBI
71	Tambaro R, Scambia G, di Maio M, Pisano C, Barletta E, Iaffaioli VR and Pignata S: The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Crit Rev Oncol Hematol. 52:33–44. 2004. View Article : Google Scholar : PubMed/NCBI
72	Pectasides D, Kamposioras K, Papaxoinis G and Pectasides E: Chemotherapy for recurrent cervical cancer. Cancer Treat Rev. 34:603–613. 2008. View Article : Google Scholar : PubMed/NCBI
73	Carl UM, Bahnsen J and Rapp W: Radiation therapy of para-aortic lymph nodes in gynaecologic cancers: techniques, results and complications. Strahlenther Onkol. 168:383–389. 1992.PubMed/NCBI
74	Grigsby PW, Vest ML and Perez CA: Recurrent carcinoma of the cervix exclusively in the paraaortic nodes following radiation therapy. Int J Radiat Oncol Biol Phys. 28:451–455. 1994. View Article : Google Scholar : PubMed/NCBI
75	Chou HH, Wang CC, Lai CH, Hong JH, Ng KK, Chang TC, Tseng CJ, Tsai CS and Chang JT: Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys. 51:442–448. 2001. View Article : Google Scholar : PubMed/NCBI
76	Singh AK, Grigsby PW, Rader JS, Mutch DG and Powell MA: Cervix carcinoma, concurrent chemoradiotherapy and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys. 61:450–455. 2005. View Article : Google Scholar : PubMed/NCBI
77	Kim JS, Kim JS, Kim SY, Kim KH and Cho MJ: Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 55:1247–1253. 2003. View Article : Google Scholar : PubMed/NCBI
78	DuPont NC and Monk BJ: Chemotherapy in the management of cervical carcinoma. Clin Adv Hematol Oncol. 4:279–286. 2006.PubMed/NCBI
79	Thigpen T, Shingleton H, Homesley H, Lagasse L and Blessing J: Cisplatin in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 48:899–903. 1981. View Article : Google Scholar : PubMed/NCBI
80	Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L and Major FJ: Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 3:1079–1085. 1985.PubMed/NCBI
81	Thigpen JT, Blessing JA, Fowler WC Jr and Hatch K: Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Cancer Treat Rep. 70:1097–1100. 1986.PubMed/NCBI
82	Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr and Hatch KD: A randomized comparison of a rapid versus prolonged (24 h) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 32:198–202. 1989. View Article : Google Scholar : PubMed/NCBI
83	Lele SB and Piver MS: Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma. Gynecol Oncol. 33:6–8. 1989. View Article : Google Scholar : PubMed/NCBI
84	Potter ME, Hatch KD, Potter MY, Shingleton HM and Baker VV: Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer. 63:1283–1286. 1989. View Article : Google Scholar : PubMed/NCBI
85	Arseneau J, Blessing JA, Stehman FB and McGehee R: A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study). Invest New Drugs. 4:187–191. 1986.PubMed/NCBI
86	McGuire WP III, Arseneau J, Blessing JA, DiSaia PJ, Hatch KD, Given FT Jr, Teng NN and Creasman WT: A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 7:1462–1468. 1989.PubMed/NCBI
87	Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL and Alberts DS: A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol. 39:332–336. 1990. View Article : Google Scholar
88	Meanwell CA, Mould JJ, Blackledge G, Lawton FG, Stuart NS, Kavanagh J, Latief TN, Spooner D and Chetiyawardana AD: Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep. 70:727–730. 1986.PubMed/NCBI
89	Sutton GP, Blessing JA, Adcock L, Webster KD and DeEulis T: Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs. 7:341–343. 1989.PubMed/NCBI
90	Sutton GP, Blessing JA, DiSaia PJ and McGuire WP: Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 49:48–50. 1993. View Article : Google Scholar : PubMed/NCBI
91	Rhomberg WU: Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II study. Cancer Treat Rep. 70:1455–1457. 1986.PubMed/NCBI
92	Morris M, Brader KR, Levenback C, Burke TW, Atkinson EN, Scott WR and Gershenson DM: Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 16:1094–1098. 1998.PubMed/NCBI
93	Lhommé C, Vermorken JB, Mickiewicz E, Chevalier B, Alvarez A, Mendiola C, Pawinski A, Lentz MA and Pecorelli S: Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer. 36:194–199. 2000.PubMed/NCBI
94	Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J and Pearl ML: Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 96:108–111. 2005. View Article : Google Scholar
95	Schilder RJ, Blessing JA, Morgan M, Mangan CE and Rader JS: Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol Oncol. 76:204–207. 2000. View Article : Google Scholar
96	Schilder RJ, Blessing J and Cohn DE: Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 96:103–107. 2005. View Article : Google Scholar
97	McGuire WP, Blessing JA, Moore D, Lentz SS and Photopulos G: Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol. 14:792–795. 1996.PubMed/NCBI
98	Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, Loyer E, Rusinkiewicz J, Gacrama P, Fueger R and Kavanagh JJ: Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Clin Cancer Res. 2:1285–1288. 1996.PubMed/NCBI
99	Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, LoCoco S, Umbreit J, Delmore JE, Arbuck S, Loyer E, Gacrama P, Fueger R and Kavanagh JJ: An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs. 8:657–661. 1997. View Article : Google Scholar : PubMed/NCBI
100	Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH and Alvarez RD: Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 19:1275–1278. 2001.PubMed/NCBI
101	Garcia AA, Blessing JA, Vaccarello L and Roman LD: Gynecologic Oncology Group Study: phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol. 30:428–431. 2007. View Article : Google Scholar : PubMed/NCBI
102	Bookman MA, Blessing JA, Hanjani P, Herzog TJ and Andersen WA: Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 77:446–449. 2000. View Article : Google Scholar : PubMed/NCBI
103	Muderspach LI, Blessing JA, Levenback C and Moore JL Jr: A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 81:213–215. 2001. View Article : Google Scholar : PubMed/NCBI
104	Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A and Kavanagh JJ: Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 15:625–631. 1997.PubMed/NCBI
105	Lhommé C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL, Lentz MA, van Glabbeke M, Matthieu-Boué A, Mignard D and Chevallier B: Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 17:3136–3142. 1999.PubMed/NCBI
106	Goedhals L, van Wiyk AL, Smith BL and Fourie SJ: Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer. 16:1172–1178. 2006. View Article : Google Scholar
107	Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ and Schorge JO: Gynecologic Oncology Group: evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 110:65–70. 2008. View Article : Google Scholar : PubMed/NCBI
108	Ferrandina G, Lorusso D, Ludovisi M, Pignata S, Sorio R, Mangili G, Breda E, Legge F, Pisconti S and Scambia G: Phase II study on pemetrexed in advanced/or recurrent cervical cancer patients: a MITO study. J Oncol. 26(Suppl 296): abs. 5515. 2008.
109	Bonomi P, Blessing J, Ball H, Hanjani P and DiSaia PJ: A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 34:357–359. 1989. View Article : Google Scholar : PubMed/NCBI
110	Kaern J, Tropé C, Sundfoer K and Kristensen GB: Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. Gynecol Oncol. 60:387–392. 1996. View Article : Google Scholar : PubMed/NCBI
111	Kaern J, Tropé C, Abeler V, Iversen T and Kjørstad K: A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer. Acta Oncol. 29:25–28. 1990. View Article : Google Scholar : PubMed/NCBI
112	Benjapibal M, Thirapakawong C, Leelaphatanadit C, Therasakvichya S and Inthasorn P: A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. Oncology. 72:33–38. 2007. View Article : Google Scholar : PubMed/NCBI
113	Daghestani N, Hakes TB, Lynch G and Lewis JL Jr: Cervix carcinoma: treatment with combination cisplatin and bleomycin. Gynecol Oncol. 16:334–339. 1983. View Article : Google Scholar : PubMed/NCBI
114	Coleman RE, Clarke JM, Slevin ML, Sweetenham J, Williams CJ, Blake P, Calman F, Wiltshaw E and Harper PG: A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. Cancer Chemother Pharmacol. 27:52–54. 1990. View Article : Google Scholar : PubMed/NCBI
115	Cervellino JC, Araujo CE, Sánchez O, Miles H and Nishihama A: Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Acta Oncol. 34:257–259. 1995. View Article : Google Scholar : PubMed/NCBI
116	Burnett AF, Roman LD, Garcia AA, Muderspach LI, Brader KR and Morrow CP: A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 76:63–66. 2000. View Article : Google Scholar : PubMed/NCBI
117	Sugiyama T, Nishida T, Kumagai S, Nishio S, Fujiyoshi K, Okura N, Yakushiji M, Hiura M and Umesaki N: Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer. 81:95–98. 1999. View Article : Google Scholar : PubMed/NCBI
118	Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M and Ohashi Y: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology. 58:31–37. 2000. View Article : Google Scholar : PubMed/NCBI
119	Rose PG, Blessing JA, Gershenson DM and McGehee R: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 17:2676–2680. 1999.
120	Papadimitriou CA, Sarris K, Moulopoulos LA, Fountzilas G, Anagnostopoulos A, Voulgaris Z, Gika D, Giannakoulis N, Diakomanolis E and Dimopoulos MA: Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol. 17:761–766. 1999.PubMed/NCBI
121	Piver MS, Ghamande SA, Eltabbakh GH and O’Neill-Coppola C: First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix – a phase II study. Gynecol Oncol. 75:334–337. 1999.
122	Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA and Fiorica JV: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 23:4626–4633. 2005. View Article : Google Scholar
123	Monk BJ, Sill MW, McMeekin SD, Cohn DE, Ramondetta LM, Boardman CH and Benda J: A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVb, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study. J Clin Oncol. 26(Suppl 294): abs. LBA 5504. 2008.
124	Wenzel LN, Huang H, Cella D, Monk BJ, Sill MW, McMeekin SD, Cohn DE, Ramondetta LM, Boardman CH and Benda J: Quality-of-life results of a randomized phase III trial of four cisplatin (Cis) containing doublet combinations in stage Ivb cervical carcinoma: a Gynecologic Oncology Group (GOG) study. J Clin Oncol. 26(Suppl 300): abs. 5529. 2008.
125	Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M and Benda J: Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 20:1832–1837. 2002. View Article : Google Scholar : PubMed/NCBI
126	Cadron I, Jakobsen A and Vergote I: Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer. Gynecol Obstet Invest. 59:126–129. 2005.PubMed/NCBI
127	Zanetta G, Fei F, Parma G, Balestrino M, Lissoni A, Gabriele A and Mangioni C: Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol. 10:1171–1174. 1999. View Article : Google Scholar : PubMed/NCBI
128	Dimopoulos MA, Papadimitriou CA, Sarris K, Aravantinos G, Kalofonos C, Gika D, Gourgoulis GM, Efstathiou E, Skarlos D and Bafaloukos D: Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol. 85:476–482. 2002. View Article : Google Scholar : PubMed/NCBI
129	Choi CH, Kim TJ, Lee SJ, Lee JW, Kim BG, Lee JH and Bae DS: Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer. 16:1157–1164. 2006. View Article : Google Scholar : PubMed/NCBI
130	Van Luijk IF, Coens C, van der Burg ME, Kobierska A, Namer M, Lhomme C, Zola P, Zanetta G and Vermorken JB; Gynecological Cancer Group of the European Organization for Research and Treatment of Cancer. Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix. Ann Oncol. 18:275–281. 2007.
131	Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, Katsaros D, Landoni F, Lissoni A, Malzoni C, Sartori E, Scollo P, Torri V, Zola P and Mangioni C: Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 23:4137–4145. 2005.
132	Mourton SM, Sonoda Y, Abu-Rustum NR, Bochner BH, Barakat RR and Chi DS: Resection of recurrent cervical cancer after total pelvic exenteration. Int J Gynecol Cancer. 17:137–140. 2007. View Article : Google Scholar : PubMed/NCBI
133	Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR and Wharton JT: Posttherapy surveillance of women with cervical cancer: an outcome analysis. Gynecol Oncol. 78:187–193. 2000. View Article : Google Scholar : PubMed/NCBI
134	Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE and Roman LD: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 27:1069–1074. 2009. View Article : Google Scholar : PubMed/NCBI
135	Coleman RL; Gynecologic Oncology Group’s. The Gynecologic Oncology Group’s role in the treatment of recurrent cervix cancer: current clinical trials. Gynecol Oncol. 110(Suppl 2): 77–80. 2008.
136	Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S and Santin AD: Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol. 106:513–520. 2007. View Article : Google Scholar
137	Goncalves A, Fabbro M, Lhommé C, Gladieff L, Extra JM, Floquet A, Chaigneau L, Carrasco AT and Viens P: A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 108:42–46. 2008. View Article : Google Scholar : PubMed/NCBI
138	Del Campo JM, Prat A, Gil-Moreno A, Pérez J and Parera M: Update on novel therapeutic agents for cervical cancer. Gynecol Oncol. 110(Suppl 2): 72–76. 2008.PubMed/NCBI
139	Hindenburg AA and Matthews L: Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. A case report. Int J Gynecol Cancer. 13:898–900. 2003. View Article : Google Scholar : PubMed/NCBI
140	Khoury-Collado F, Bowes RJ, Jhamb N, Aghajanian C and Abu-Rustum NR: Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series. Gynecol Oncol. 105:823–825. 2007. View Article : Google Scholar : PubMed/NCBI